Upcoming Events
Past Events
Videos Documenting Functional Change Following
NVG-291 Treatment in the CONNECT SCI Study
The videos below present visual documentation from the CONNECT SCI Study showing participants performing a standardized
10-meter walking assessment at baseline and after 12 weeks of NVG-291 treatment. These side-by-side recordings highlight the functional impact of NVG-291 treatment, including observable changes in gait, balance, coordination, and walking efficiency
NervGen Pharma Corp (“NervGen”) (NASDAQ: NGEN), is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. NervGen’s lead therapeutic candidate, NVG-291, is a first- and potentially best-in-class subcutaneously administered candidate being evaluated in the Phase 1b/2a CONNECT SCI Study in individuals living with spinal cord injury. Through NVG-291 and the Company’s next-generation candidate, NVG-300, NervGen is pursuing a pharmacologic approach to transform the treatment paradigm for neurotraumatic and neurologic conditions with significant unmet medical need.
Contact
112-970 Burrard Street
Unit 1290
Vancouver, BC V6Z 2R4
Phone: (778) 731-1711
Email: info@nervgen.com